Ameriprise’s Syneos Health, Inc. Class A Common Stock SYNH Stock Holding History

Ameriprise’s Portfolio SYNH Stock Details SYNH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-253,993	Closed	-$10.7M	–	4000
2023 Q2	$10.7M	Sell	253,993 -1,165,381	-82%	-$47.1M	﹤0.01%	1719
2023 Q1	$50.6M	Buy	1,419,374 +278,953	+24%	+$10.1M	0.02%	752
2022 Q4	$41.8M	Sell	1,140,421 -343,438	-23%	-$13.6M	0.01%	807
2022 Q3	$70M	Buy	1,483,859 +184,022	+14%	+$11.9M	0.03%	576
2022 Q2	$93.2M	Buy	1,299,837 +59,447	+5%	+$4.35M	0.03%	504
2022 Q1	$100M	Buy	1,240,390 +23,775	+2%	+$2.01M	0.03%	531
2021 Q4	$125M	Buy	1,216,615 +68,049	+6%	+$6.53M	0.03%	484
2021 Q3	$100M	Buy	1,148,566 +346,838	+43%	+$31.4M	0.03%	522
2021 Q2	$71.7M	Buy	801,728 +357,768	+81%	+$30.2M	0.02%	645
2021 Q1	$33.7M	Buy	443,960 +25,470	+6%	+$1.92M	0.01%	973
2020 Q4	$28.5M	Sell	418,490 -20,784	-5%	-$1.3M	0.01%	1018
2020 Q3	$23.4M	Sell	439,274 -216,906	-33%	-$12.9M	0.01%	990
2020 Q2	$38.2M	Sell	656,180 -80,583	-11%	-$4.33M	0.02%	713
2020 Q1	$29M	Buy	736,763 +112,297	+18%	+$6.57M	0.02%	759
2019 Q4	$37.2M	Buy	624,466 +138,892	+29%	+$7.47M	0.02%	835
2019 Q3	$25.8M	Buy	485,574 +208,083	+75%	+$10.7M	0.01%	969
2019 Q2	$14.2M	Buy	277,491 +4,012	+1%	+$187K	0.01%	1447
2019 Q1	$14.2M	Sell	273,479 -4,851	-2%	-$235K	0.01%	1403
2018 Q4	$11M	Buy	278,330 +108,631	+64%	+$5.05M	0.01%	1525
2018 Q3	$8.75M	Buy	169,699 +11,456	+7%	+$561K	﹤0.01%	1976
2018 Q2	$7.42M	Buy	158,243 +377	+0.2%	+$15.6K	﹤0.01%	1967
2018 Q1	$5.61M	Sell	157,866 -121,642	-44%	-$4.76M	﹤0.01%	2095
2017 Q4	$12.2M	Sell	279,508 -127,596	-31%	-$5.96M	0.01%	1462
2017 Q3	$21.3M	Sell	407,104 -6,729	-2%	-$375K	0.01%	998
2017 Q2	$24.2M	Buy	413,833 +98,110	+31%	+$5.1M	0.01%	899
2017 Q1	$14.5M	Sell	315,723 -4,536	-1%	-$226K	0.01%	1245
2016 Q4	$16.8M	Sell	320,259 -22,193	-6%	-$1.07M	0.01%	1110
2016 Q3	$15.3M	Buy	342,452 +75,166	+28%	+$3.26M	0.01%	1101
2016 Q2	$10.2M	Sell	267,286 -45,765	-15%	-$2.01M	0.01%	1369
2016 Q1	$12.9M	Buy	313,051 +27,098	+9%	+$1.12M	0.01%	1227
2015 Q4	$13.9M	Buy	285,953 +15,473	+6%	+$688K	0.01%	1194
2015 Q3	$10.8M	Sell	270,480 -37,375	-12%	-$1.63M	0.01%	1402
2015 Q2	$12.4M	Buy	307,855 +36,931	+14%	+$1.27M	0.01%	1399
2015 Q1	$8.87M	Sell	270,924 -36,570	-12%	-$1.01M	0.01%	1654
2014 Q4	$7.9M	Buy	+307,494	New	+$7.31M	﹤0.01%	1712

Other funds holding SYNH

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Natixis Advisors Boston, Massachusetts $71.9B AUM 28.03% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Nomura Asset Management Tokyo, Japan $38.8B AUM 30.94% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

CFB

Cullen/Frost Bankers San Antonio, Texas $8.81B AUM 22.47% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ameriprise's SYNH Position: Q3 2023 in Review

Ameriprise sold out of Syneos Health, Inc. Class A Common Stock (SYNH) in Q3 2023, closing a stake of 253,993 shares — an estimated $10.7M sold.

Ameriprise first reported a position in SYNH in Q4 2014 and held it in 35 quarters. The position peaked at $125M in Q4 2021. 10 funds tracked by Wall St. Rank hold SYNH as of Q3 2023.

Ameriprise reported no remaining Syneos Health, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Ameriprise sold 253,993 Syneos Health, Inc. Class A Common Stock shares in Q3 2023, an estimated $10.7M.
Ameriprise first reported a position in Syneos Health, Inc. Class A Common Stock in Q4 2014 and held it in 35 quarters.
Ameriprise's Syneos Health, Inc. Class A Common Stock position peaked at $125M in Q4 2021.
10 funds tracked by Wall St. Rank held Syneos Health, Inc. Class A Common Stock as of Q3 2023.

Based on Ameriprise's 13F filing for Q3 2023, filed 14 Nov 2023.